OnCo

Basal cell carcinoma: lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersRisk group
Early / localised·1
Advanced, first line1·
Second line·1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
Risk groupLow-riskStandard excision with 4 mm margin, curettage and electrodesiccation, or topical imiquimod / 5-FU / photodynamic therapy for superficial lesions.43

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersLocally advanced or metastaticVismodegib or sonidegib; cemiplimab after hedgehog-inhibitor failure or intolerance; multidisciplinary review for surgery/radiotherapy after response.81

Second line

SubgroupSettingApproachProducts and trialsEvidence
Risk groupHigh-risk or recurrentMohs micrographic surgery or excision with complete margin assessment; radiotherapy if surgery not feasible.91

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.